Treatment Results

Female patient, 48 years old. Presented with newly diagnosed breast cancer, stage IIA. Immunohistochemical testing revealed a HER2-positive subtype. Before seeing me, she was offered a standard chemotherapy protocol without considering the molecular profile of the tumor.

I ordered extended molecular profiling of the tumor, which confirmed the HER2-positive status and helped clarify the biological characteristics. Based on the results, I prescribed a combination regimen: anti-HER2 targeted therapy combined with chemotherapy. I developed the treatment plan according to current international guidelines (NCCN, ESMO) and adapted it to the patient’s individual needs.

Male patient, 62 years old. Diagnosed with sigmoid colon cancer, stage IIIB, after surgical treatment. Came for a consultation regarding adjuvant (post-operative) therapy. Previously offered standard chemotherapy without molecular testing.

I ordered comprehensive molecular testing of the tumor: microsatellite instability (MSI) status, BRAF and KRAS mutations. The results allowed me to select the optimal adjuvant chemotherapy regimen and determine the prognosis. I personalized the treatment plan based on the molecular characteristics of the tumor and the patient’s individual features.

Male patient, 57 years old. Diagnosed with unresectable hepatocellular carcinoma (HCC). Sought a second opinion after another institution recommended only supportive care. The patient and his family wanted to confirm that all treatment options had been considered.

After carefully analyzing imaging data and liver function status, I proposed a combination regimen: targeted therapy with immunotherapy (based on IMbrave150 trial data). This regimen demonstrated significant survival benefit in unresectable HCC in international clinical trials. I coordinated the treatment plan with a multidisciplinary team.

Female patient, 54 years old. Diagnosed with metastatic cutaneous melanoma. Molecular genetic testing revealed a BRAF V600E mutation — a key biomarker that determines treatment strategy. Had previously received standard chemotherapy without significant effect.

As a first step, I prescribed combination targeted therapy with BRAF and MEK inhibitors — a regimen specifically targeting the BRAF V600E mutation. After achieving a response to targeted therapy, I transitioned the patient to immunotherapy to consolidate the result and ensure long-term disease control.

Female patient, 51 years old. Diagnosed with high-grade serous ovarian cancer, stage IIIC. After surgery, she sought a second opinion regarding further treatment. The previous institution recommended only standard chemotherapy without molecular testing.

I recommended testing for BRCA1/2 gene mutations — a key predictive biomarker in ovarian cancer. The result was positive, opening the possibility of PARP inhibitors as maintenance therapy. This modern class of drugs significantly increases progression-free time in patients with BRCA mutations.